食品安全情報(化学物質)No. 24/ 2020
パー及びポリフルオロアルキル化合物(pfas)についてのよくある質問 Frequently asked questions about per- and polyfluoroalkyl substances (PFAS) 12.10.2020
Tags:
Frequently, Substance, Pfas, Polyfluoroalkyl, And polyfluoroalkyl substances
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document:
Advertisement
Documents from same domain
Guideline for the Development of Liposome Drug …
www.nihs.go.jp4 described in this document are also subject to other relevant notifications and guidelines. The active substances mentioned here include a low-molecular-weight chemical entity, a
NIHS 医薬品安全性情報 Vol.16 No.012018/0111/
www.nihs.go.jpCarafate’]の製品表示が改訂され, 販売名が[‘Carafate suspension’]から [‘Carafate oral suspension’]に変更さ
Guideline for Bioequivalence Studies of Generic …
www.nihs.go.jp1 Guideline for Bioequivalence Studies of Generic Products for Topical Use July 7, 2003 局所皮膚適用製剤の後発医薬品のための 生物学的同等性試験ガイドライン
Since 1874 遺伝子治療用製品の開発における 国内 …
www.nihs.go.jp遺伝子治療の現状 海外の遺伝子治療の規制と国際調和 日本の遺伝子治療と関連規制 遺伝子治療指針の改正
Guideline for Bioequivalence Studies for Different ...
www.nihs.go.jp2 Section 1: Introduction This guideline describes the principles of procedures of bioequivalence studies for oral solid dosage forms that contains a different quantity of the active ingredient from an
Guidelines, Studies, Solid, Dosage, Guideline for bioequivalence studies for, Bioequivalence, Solid dosage
Clinical Pharmacokinetic Studies of Pharmaceuticals
www.nihs.go.jp- 1 - Clinical Pharmacokinetic Studies of Pharmaceuticals This document is an informal translation of the official text that was promulgated in Japanese on
Pharmaceutical, Clinical, Studies, Clinical pharmacokinetic studies of pharmaceuticals, Pharmacokinetic
平成 25 年度報告 毒物劇物指定の ... - nihs.go.jp
www.nihs.go.jp平成. 25 年度報告 毒物劇物指定のための有害性情報の収集・評価. 物質名: n-(2-
毒物及び劇物取締法Q&A - nihs.go.jp
www.nihs.go.jp1 平成29年3月31日更新 毒物及び劇物取締法Q&A 質問一覧 1.毒物及び劇物取締法について ..... 4
European Medicines Agency - NIHS
www.nihs.go.jpWhat is Quality Risk Management? • Proposed ICH Q9 definition: “Quality risk management is a systematic process for the identification, assessment
Management, European, Quality, Risks, Agency, Quality risk management, Medicine, European medicines agency, Nihs, Ich q9
ICH Q9 ‘Quality Risk Management’ - NIHS
www.nihs.go.jpICH Q9 ‘Quality Risk Management’ - an industry view Peter H. Gough, Eli Lilly and Company
Management, Quality, Risks, Nihs, Ich q9 quality risk management nihs, Ich q9 quality risk management
Related documents
History and Use of Per- and Polyfluoroalkyl Substances …
pfas-1.itrcweb.orgThe unique physical and chemical properties of per- and polyfluoroalkyl substances (PFAS) impart oil and water repellency, temperature resistance, and friction reduction to a wide range of products used by consumers and industry. For example, PFAS, have …
Substance, Pfas, Polyfluoroalkyl, And polyfluoroalkyl substances
Naming Conventions and Physical and Chemical ... - PFAS
pfas-1.itrcweb.orgThe family of nonpolymeric PFAS encompasses two major classes: perfluoroalkyl substances and polyfluoroalkyl substances, which include many subgroups of chemicals, examples of which are shown in Figure 2-1. Table 2-1 provides general classification and chemical structures, examples of each class, and primary uses of the nonpolymer PFAS
Substance, Pfas, Polyfluoroalkyl, Substances and polyfluoroalkyl substances
Draft PFAS Monitoring Plan
www.pca.state.mn.usPFAS release to the environment or the most likely to support source reduction activities. Altogether, this monitoring plan is designed to identify the largest and most environmentally significant sources of PFAS pollution as expeditiously as possible – working both with waste management conduits to identify their